Several large-scale human studies, including SUSTAIN-6 for semaglutide and LEADER for liraglutide, have found no significant increase in the risk of MTC or other thyroid cancers compared to placebo groups
Schauer PR, Bhatt DL, Kirwan JP et al (2017) Bariatric surgery versus intensive medical therapy for diabetes5-year outcomes
The FDA does not approve compounded medications for safety or efficacy
When first studied, researchers primarily wanted to ensure they were safe for the heart
These findings support the real-world therapeutic effectiveness of oral semaglutide outside highly controlled clinical trials
Most GLP-1 side effects are gastrointestinal, mild, and improve within the first few weeks of each dose level Serious warning signs severe abdominal pain, persistent vomiting, or allergic reactions are rare but require immediate medical attention Wegovy, Zepbound, and Foundayo share a similar GI side-effect profile, with some differences in nausea and diarrhea frequency In-person monitoring at PEAK allows your clinician to catch issues early and adjust your titration schedule in real time Starting a GLP-1 medication like Wegovy (semaglutide), Zepbound (tirzepatide), or Foundayo (orforglipron) is a major step toward better health and it is completely normal to wonder what to expect along the way